Revised: July 16, 2026

People want simple answers to complex problems. Atherosclerotic plaque—that fatty, inflammatory buildup inside artery walls—feels like something you should be able to “clean out” like a clogged pipe. That hope fuels massive interest in supplements that promise to “dissolve plaque,” “unclog arteries,” or “reverse heart disease naturally.”
Nattokinase is currently one of the most popular supplements in this category. An enzyme derived from natto (fermented soybeans), it is widely marketed for circulation, blood pressure, and plaque reversal. But marketing is not evidence.
To understand the reality, we need to look at what human clinical research actually shows: what doses were used, what outcomes were measured, and how it compares to other supplements with plaque-relevant data, such as aged garlic extract, omega-3s, and vitamin K2.¹–¹¹
(Disclosure: This is educational information, not medical advice. If you have known plaque or take blood thinners, consult your clinician before adding supplements.)
Atherosclerosis isn’t just cholesterol stuck to an artery wall; it is a living lesion containing immune cells, fibrous tissue, and often calcium. “Reversing” it doesn’t just mean shrinking it—it also means stabilizing it so it is less likely to rupture.
When researchers measure reversal, they don’t rely on how a patient “feels.” They use reproducible imaging:
Real claims of regression require this kind of hard data, ideally from randomized controlled trials (RCTs).
Nattokinase is a fibrinolytic enzyme—it breaks down fibrin, a protein that forms the mesh of blood clots. This often confuses people.
While nattokinase may improve blood flow by affecting clotting factors, that does not automatically mean it “scrubs” plaque out of the vessel wall. The real question is: Does this biological mechanism translate to shrinking plaque in humans?
The most critical study for anyone considering this supplement is the Nattokinase Atherothrombotic Prevention Study (NAPS).²,¹⁰ This was a randomized, double-blind, placebo-controlled trial—the gold standard of research.
The Result: At the standard 2,000 FU dose, the study did not find that nattokinase slowed the progression of atherosclerosis compared to placebo.²
This doesn’t mean nattokinase is useless, but it is a reality check. The best-designed trial we have at the most common dose failed to support the “plaque reversal” narrative.
You will often hear about other studies that claim positive results, such as the trial by Ren et al. (2017).³ This study focused on patients with carotid atherosclerosis and hyperlipidemia and reported benefits.
Why the discrepancy? In supplement research, we often see a pattern where smaller, pilot studies or those using higher doses show promise, while larger, more rigorous trials show null results. While the positive data exists, it has not been consistently replicated in multi-center trials with standardized imaging.³
The Verdict: While there are signals of benefit in specific populations, we lack the definitive, high-quality evidence needed to claim it works for everyone.
While plaque regression is unproven, nattokinase is not an inert pill. It has measurable effects on physiology.
If your goal is modulating risk factors like blood pressure, the evidence is stronger than it is for dissolving plaque.
Because nattokinase influences the clotting system, “natural” does not mean “risk-free.”
If your main goal is stabilizing or reducing plaque, how does nattokinase stack up against the competition?
Tier 1: Strongest Human Imaging Data
Tier 2: Mechanism-Based or Mixed Data
If you are taking nattokinase 2,000 FU expecting it to scour your arteries clean, the best science we have (the NAPS trial) suggests you may be disappointed.
However, if you view it as part of a broader strategy to manage blood pressure and blood viscosity, it has a role. But for those strictly focused on coronary plaque, the human imaging data for Aged Garlic Extract and pharmaceutical-grade Omega-3s is currently superior.
Transparency Note: This article was created with assistance from AI tools. The final content has been carefully reviewed and edited by the author, who is responsible for its accuracy. This site is supported by an Advisory Board of researchers. All content is for educational purposes only and does not constitute medical advice.
Educational family-history heart risk calculator with H-score insights, visual family tree input and shareable PDF reports.